行情

REPH

REPH

Recro Pharma
NASDAQ

实时行情|Nasdaq Last Sale

13.10
+0.92
+7.55%
盘后: 13.10 0 0.00% 16:00 10/21 EDT
开盘
12.33
昨收
12.18
最高
13.18
最低
12.10
成交量
35.23万
成交额
--
52周最高
13.13
52周最低
5.53
市值
2.94亿
市盈率(TTM)
-4.7143
分时
5日
1月
3月
1年
5年

分析师评级

5位分析师的综合评级

强力推荐

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

REPH 新闻

  • 中概股收盘:蔚来汽车收涨11.2% 万达体育跌超8%
  • 新浪美股.50分钟前
  • Facebook为2020年美国大选推出打击虚假信息新举措
  • 新浪美股.1小时前
  • Recro Pharma, Inc.'s (NASDAQ:REPH) Shift From Loss To Profit
  • Simply Wall St..2小时前
  • 收盘:美股小幅收高 三大股指逼近历史最高纪录
  • 新浪美股.2小时前

更多

所属板块

生物技术和医学研究
+1.34%
制药与医学研究
+0.39%

热门股票

名称
价格
涨跌幅

REPH 简况

Recro Pharma, Inc. is a clinical-stage specialty pharmaceutical company. The Company is engaged in developing products for hospitals and ambulatory care settings that is developing non-opioid products for treatment of serious acute pain. The Company's lead product candidate is an injectable form of meloxicam. Its product candidates for pain indications include injectable meloxicam, a product candidate in development for the treatment of acute post-operative pain; Dex-IN, a product candidate under development for the treatment of post-operative pain; Dex-SL, a product candidate for the treatment of chronic pain, and Fadolmidine (Fado), a product candidate used by injection into the spine for pain associated with surgery or certain types of chronic pain and which the Company pursues as a topical product for local application to treat serious pain associated with nerve damage to local tissues (neuropathies), especially of the lower extremities, which can occur in diabetic patients.
展开

Webull提供Recro Pharma Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。